GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer
Jing Yang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yunsheng Yang(Chinese PLA General Hospital), Zhongsheng Lu(Chinese PLA General Hospital), Yao Wang(Chinese PLA General Hospital), Xiangdong Wang(Shandong University), Jing Wen(Guangdong Academy of Agricultural Sciences), Tian Tian(Chinese Academy of Medical Sciences & Peking Union Medical College), Zikai Wang(Chinese PLA General Hospital)
Cited by 71
Related Papers
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
|Gastroenterology|2016|696
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
|mSystems|2018|322
Challenges in the management of acute peptic ulcer bleeding
|The Lancet|2013|234